newsfilter
← Latest News
GlobeNewswire·

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024

- Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study